Ursodeoxycholic Acid (UDCA) in Congestive Hepatopathy

Mechanistic Rationale

UDCA exhibits anticholestatic effects across a range of cholestatic liver diseases, protecting hepatocytes and cholangiocytes from toxic bile acids and enhancing bile‑acid–dependent secretion pathways【1】【2】.

Initiate UDCA at 13–15 mg/kg/day divided into two to three doses; this regimen is the standard therapeutic dose shown to be effective in primary biliary cholangitis【1】【2】【3】.
The FDA‑approved dose for cholestatic conditions is 8–10 mg/kg/day, but hepatology guideline panels recommend the higher 13–15 mg/kg/day range for optimal efficacy【1】【2】【4】.
Doses exceeding 25 mg/kg/day should be avoided in patients with cirrhosis or advanced liver disease because high‑dose UDCA (28–30 mg/kg/day) has been associated with harm in such populations【5】.

Evaluate biochemical response at 6 months by measuring serial liver tests (alkaline phosphatase, γ‑glutamyl transferase, bilirubin, and transaminases) to determine therapeutic effect【1】【2】.

No high‑quality, condition‑specific trials exist for UDCA in congestive hepatopathy; current recommendations are extrapolated from evidence in other cholestatic disorders【1】【2】.
High‑dose UDCA (>25 mg/kg/day) has demonstrated potential toxicity in primary sclerosing cholangitis trials, reinforcing the need for dose caution in advanced liver disease【6】【7】【5】.
Long‑term safety of UDCA has been established over decades in cholestatic liver diseases, with a generally favorable tolerability profile【1】【2】.